|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
956,580,000 |
Market
Cap: |
866.07(B) |
Last
Volume: |
3,374,911 |
Avg
Vol: |
3,268,697 |
52
Week Range: |
$434.7 - $909.04 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 720 |
Guru Rank Value : 1.4 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
656 |
Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
1,520,577 |
2,391,327 |
3,771,329 |
6,318,238 |
Total Sell Value |
$1,284,658,855 |
$1,892,909,435 |
$2,147,483,647 |
$2,147,483,647 |
Total People Sold |
3 |
3 |
4 |
6 |
Total Sell Transactions |
18 |
31 |
50 |
93 |
End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ricks David A |
SVP and Pres, Lilly Bio-Meds |
|
2016-02-03 |
4 |
AS |
$76.73 |
$188,756 |
D/D |
(2,460) |
79,403 |
|
- |
|
Fry Stephen F |
SVP, HR & Diversity |
|
2016-02-03 |
4 |
AS |
$76.46 |
$55,434 |
D/D |
(725) |
74,920 |
|
- |
|
Tai Jackson P |
Director |
|
2016-02-01 |
4 |
B |
$78.62 |
$249,225 |
D/D |
3,170 |
39,487 |
2.39 |
- |
|
Simmons Jeffrey N |
SVP&Pres. Elanco Animal Health |
|
2016-02-01 |
4 |
D |
$79.10 |
$360,142 |
D/D |
(4,553) |
113,990 |
|
- |
|
Simmons Jeffrey N |
SVP&Pres. Elanco Animal Health |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,843 |
118,543 |
|
- |
|
Walsh Fionnuala M |
SVP, Global Quality |
|
2016-02-01 |
4 |
D |
$79.10 |
$154,166 |
D/D |
(1,949) |
54,645 |
|
- |
|
Walsh Fionnuala M |
SVP, Global Quality |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,144 |
56,594 |
|
- |
|
Rice Derica W |
EVP-Global Services and CFO |
|
2016-02-01 |
4 |
AS |
$78.36 |
$512,945 |
D/D |
(6,546) |
40,868 |
|
- |
|
Rice Derica W |
EVP-Global Services and CFO |
|
2016-02-01 |
4 |
D |
$79.10 |
$723,449 |
D/D |
(9,146) |
47,414 |
|
- |
|
Rice Derica W |
EVP-Global Services and CFO |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,685 |
56,560 |
|
- |
|
Peterson Barton R |
Sr. VP, Corp. Affairs & Comm. |
|
2016-02-01 |
4 |
D |
$79.10 |
$211,988 |
D/D |
(2,680) |
94,208 |
|
- |
|
Peterson Barton R |
Sr. VP, Corp. Affairs & Comm. |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,698 |
96,888 |
|
- |
|
Ricks David A |
SVP and Pres, Lilly Bio-Meds |
|
2016-02-01 |
4 |
AS |
$78.36 |
$256,472 |
D/D |
(3,273) |
81,863 |
|
- |
|
Ricks David A |
SVP and Pres, Lilly Bio-Meds |
|
2016-02-01 |
4 |
D |
$79.10 |
$368,290 |
D/D |
(4,656) |
85,136 |
|
- |
|
Ricks David A |
SVP and Pres, Lilly Bio-Meds |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,843 |
89,792 |
|
- |
|
Lundberg Jan M |
EVP,Science&Tech and Pres. LRL |
|
2016-02-01 |
4 |
D |
$79.10 |
$578,063 |
D/D |
(7,308) |
114,734 |
|
- |
|
Lundberg Jan M |
EVP,Science&Tech and Pres. LRL |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,541 |
122,042 |
|
- |
|
Mahony Susan |
SVP & Pres., Lilly Oncology |
|
2016-02-01 |
4 |
D |
$79.10 |
$366,154 |
D/D |
(4,629) |
86,895 |
|
- |
|
Mahony Susan |
SVP & Pres., Lilly Oncology |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,843 |
91,524 |
|
- |
|
Harrington Michael J |
Senior VP and General Counsel |
|
2016-02-01 |
4 |
D |
$79.10 |
$331,745 |
D/D |
(4,194) |
59,915 |
|
- |
|
Harrington Michael J |
Senior VP and General Counsel |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,066 |
64,109 |
|
- |
|
Lechleiter John C |
Chairman, President and CEO |
|
2016-02-01 |
4 |
D |
$79.10 |
$1,734,109 |
D/D |
(21,923) |
751,188 |
|
- |
|
Lechleiter John C |
Chairman, President and CEO |
|
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,623 |
773,111 |
|
- |
|
Fry Stephen F |
SVP, HR & Diversity |
|
2016-02-01 |
4 |
AS |
$78.39 |
$189,077 |
D/D |
(2,412) |
75,645 |
|
- |
|
Fry Stephen F |
SVP, HR & Diversity |
|
2016-02-01 |
4 |
D |
$79.10 |
$269,731 |
D/D |
(3,410) |
78,057 |
|
- |
|
1436 Records found
|
|
Page 47 of 58 |
|
|